Increased prevalence of gastrointestinal symptoms associated with impaired quality of life in renal transplant recipients.
(2007) In Transplantation 83(3). p.282-289- Abstract
- Background. Immunosuppressive therapies have been associated with gastrointestinal (GI) side effects, which may impair health-related quality of life (HRQoL). Methods. In this survey, 4,232 renal transplant recipients from Denmark, Finland, Nor-way, and Sweden completed the Short-Form 36 (SF-36) questionnaire and the Gastrointestinal Symptom Rating Scale (GSRS). SF-36 scores were compared with country norm values. Multiple logistic regression analysis was used to identify immunosuppressants associated with GI symptoms. Results. The prevalence of troublesome GI symptoms (GSRS > 1) was 83% for indigestion, 69% for abdominal pain, 58% for constipation, 53% for diarrhea, 47% for reflux, and 92% for any GI symptom. Compared with the general... (More)
- Background. Immunosuppressive therapies have been associated with gastrointestinal (GI) side effects, which may impair health-related quality of life (HRQoL). Methods. In this survey, 4,232 renal transplant recipients from Denmark, Finland, Nor-way, and Sweden completed the Short-Form 36 (SF-36) questionnaire and the Gastrointestinal Symptom Rating Scale (GSRS). SF-36 scores were compared with country norm values. Multiple logistic regression analysis was used to identify immunosuppressants associated with GI symptoms. Results. The prevalence of troublesome GI symptoms (GSRS > 1) was 83% for indigestion, 69% for abdominal pain, 58% for constipation, 53% for diarrhea, 47% for reflux, and 92% for any GI symptom. Compared with the general population, HRQoL was most commonly meaningfully impaired in the general health dimension (53% of patients). The presence and severity of GI symptoms were associated with worse HRQoL. Tacrolimus showed a significant association with diarrhea (odds ratio [OR]: 1.7; 95% confidence interval [CI]: 1.4-2.0) and constipation (OR: 1.3; 95% Cl: 1.1-1.6), and sirolimus with indigestion (OR: 2.9; 95% Cl: 1.0-8.1) and abdominal pain (OR: 2.2; 95% Cl: 1.1-4.4). Conclusions. GI symptoms are associated with impaired HRQoL in the renal transplant population. Managing GI symptoms by careful choice of immunosuppressants should be a focus for improving HRQoL in renal transplant recipients (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/165738
- author
- Ekberg, Henrik LU ; Kyllonen, Lauri ; Madsen, Soren ; Grave, Gisle ; Solbu, Dag and Holdaas, Hallvard
- organization
- publishing date
- 2007
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Transplantation
- volume
- 83
- issue
- 3
- pages
- 282 - 289
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- wos:000244375900010
- scopus:33846980744
- ISSN
- 1534-6080
- DOI
- 10.1097/01.tp.0000251923.14697.f5
- language
- English
- LU publication?
- yes
- id
- b40511f5-166a-4108-8474-19b10ff118d0 (old id 165738)
- alternative location
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17297402&dopt=Abstract
- date added to LUP
- 2016-04-01 15:56:58
- date last changed
- 2022-02-27 17:48:47
@article{b40511f5-166a-4108-8474-19b10ff118d0,
abstract = {{Background. Immunosuppressive therapies have been associated with gastrointestinal (GI) side effects, which may impair health-related quality of life (HRQoL). Methods. In this survey, 4,232 renal transplant recipients from Denmark, Finland, Nor-way, and Sweden completed the Short-Form 36 (SF-36) questionnaire and the Gastrointestinal Symptom Rating Scale (GSRS). SF-36 scores were compared with country norm values. Multiple logistic regression analysis was used to identify immunosuppressants associated with GI symptoms. Results. The prevalence of troublesome GI symptoms (GSRS > 1) was 83% for indigestion, 69% for abdominal pain, 58% for constipation, 53% for diarrhea, 47% for reflux, and 92% for any GI symptom. Compared with the general population, HRQoL was most commonly meaningfully impaired in the general health dimension (53% of patients). The presence and severity of GI symptoms were associated with worse HRQoL. Tacrolimus showed a significant association with diarrhea (odds ratio [OR]: 1.7; 95% confidence interval [CI]: 1.4-2.0) and constipation (OR: 1.3; 95% Cl: 1.1-1.6), and sirolimus with indigestion (OR: 2.9; 95% Cl: 1.0-8.1) and abdominal pain (OR: 2.2; 95% Cl: 1.1-4.4). Conclusions. GI symptoms are associated with impaired HRQoL in the renal transplant population. Managing GI symptoms by careful choice of immunosuppressants should be a focus for improving HRQoL in renal transplant recipients}},
author = {{Ekberg, Henrik and Kyllonen, Lauri and Madsen, Soren and Grave, Gisle and Solbu, Dag and Holdaas, Hallvard}},
issn = {{1534-6080}},
language = {{eng}},
number = {{3}},
pages = {{282--289}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{Transplantation}},
title = {{Increased prevalence of gastrointestinal symptoms associated with impaired quality of life in renal transplant recipients.}},
url = {{http://dx.doi.org/10.1097/01.tp.0000251923.14697.f5}},
doi = {{10.1097/01.tp.0000251923.14697.f5}},
volume = {{83}},
year = {{2007}},
}